Unlocking the Potential of Aptamers
About Triera Biosciences
Driven to Surpass What’s Possible
At Triera Biosciences, the pursuit of innovation is deeply intertwined with a commitment to real-world impact. Our team, comprised of leading scientists and experts across academia and business, collaborates with private and public sectors to advance the field of aptamer research. Our ultimate goal is far more than academic or even scientific: it’s profoundly human.
"I am convinced that this aptamer and delivery system have immense potential to transform prevention and treatments of SARS-CoV-2."
Matthew Miller, Associate Professor, Department of Biochemistry and Biomedical Sciences, McMaster University
This unwavering commitment to improving people’s lives is what sets Triera Biosciences apart, positioning us at the thrilling intersection of scientific excellence and human potential.
Triera Biosciences and McMaster University
Triera Biosciences has partnered with McMaster University in an exclusive, worldwide agreement to develop aptamer therapeutic platforms for the next 20 years. Our combined expertise and mutual capabilities offer significant advantages in the development process, including:
Significantly Reduced Cost
New drug development costs on average between $100-200M USD. McMaster University’s existing internal resources and facilities dramatically lower these costs.
Greatly Improved Speed
Broad applicability and process of aptamer development for new therapeutic targets allows us to reach clinical trials a lot faster than industry average.
Key Personnel
McMaster University
Dr. Yingfu Li
Professor, Department of Biochemistry & Biomedical Sciences
Dr. Li earned a Ph.D. in Biochemistry from Simon Fraser University, and has earned many accolades in his career since: Governor General Academic Gold Medal, Engineering Research Council of Canada Doctoral Prize, and awarded postdoctoral fellow of the Medical Research Council of Canada. Following notable postdoctoral studies at Yale University, his research at McMaster has focused on aptamers and DNAzymes, where he has gained a global reputation as a leader in the field.
Dr. Matthew Miller
Associate Professor, Department of Biochemistry & Biomedical Sciences
Dr. Miller completed his PhD at the University of Western Ontario studying the molecular virology of DNA viruses, and then conducted postdoctoral research at the Icahn School of Medicine focusing on characterizing the innate and adaptive immune responses to viral infection. His innovative and groundbreaking work has been instrumental in the ongoing development of a ‘universal’ influenza virus vaccine.
Triera Biosciences
Greg Fenton
Interim CEO, Triera Biosciences
Greg Fenton is a seasoned investment professional with a Bay Street career spanning nearly 30 years, including work in various capacities with ever-increasing responsibility in both the Canadian banking and investment management sectors. His experience spans many disciplines: capital markets, investment management, actuarial, pension, insurance, accounting, tax, and risk management.
Dr. Colin van der Kuur
CSO, Triera Biosciences
Dr. van der Kuur was the first graduate from University of Guelph with a Specialized Honours in Chemical Physics in 1993, and subsequently completed a doctorate in leadership in 2010. Through his leadership, Zentek is rapidly expanding a high-value IP portfolio through internal research, collaboration, and licensing world-leading technology.
Zentek Ltd.: Improving Lives Through Nanotechnology
Triera Biosciences is a wholly owned subsidiary of Zentek Ltd., an IP development and commercialization company harnessing the power of cutting-edge technologies including nanomaterials and graphene. Zentek and Triera Biosciences share the same guiding mission: developing innovative new solutions that quantifiably improve people’s lives on multiple fronts.